Compare ResMed Inc. (RMD) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ProShares Ultra Gold ETF — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while ProShares Ultra Gold ETF trades at $51.84. The key difference: ResMed Inc. pays a 1.19% dividend while ProShares Ultra Gold ETF pays none, and ResMed Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| RMD | UGL | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $283.28 | $85.62 |
52-Week Low | $182.82 | $41.14 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
UGL shares declined 3.43% to $50.61, reflecting bearish technical momentum with the stock trading near key support levels. The technical picture shows oversold conditions with RSI at 25.52 suggesting potential near-term bounce, while moving averages indicate sustained downward pressure. Recent gold market volatility driven by inflation data and Fed policy expectations creates headwinds for gold-related equities.
The outlook remains cautious as UGL faces pressure from rising interest rate expectations and gold price volatility. Investment opportunity exists for contrarian investors given oversold technical conditions, but risks include persistent Fed hawkishness and gold price weakness. Key catalysts include upcoming inflation data and Fed policy decisions that will drive gold market direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
